Tiotropium

Introduction Overview

Generic Name

tiotropium

Brand Name

Spiriva, Spiriva Respimat

Dosage Form

inhalation (capsule for oral inhalation via HandiHaler device, aerosol spray via Respimat inhaler)

Drug Class

Anticholinergic bronchodilators

Pharmacokinetics

Absorption:
Tiotropium is administered via inhalation, delivering the drug directly to the lungs, which facilitates rapid onset of action and localized bronchodilation. When inhaled, a small fraction of the dose is deposited in the lungs and absorbed through the respiratory epithelium. A substantial portion of the drug may be swallowed and absorbed via the gastrointestinal tract. Oral bioavailability is relatively low, estimated at approximately 19.5%, due to poor gastrointestinal absorption and extensive first-pass metabolism. Peak plasma concentrations occur about 5 to 7 minutes following inhalation via the Respimat inhaler and approximately 30 minutes with the HandiHaler capsules.

Distribution:
Tiotropium exhibits a large apparent volume of distribution of about 32 L/kg, indicating widespread tissue distribution. It is moderately bound to plasma proteins (approximately 72%), primarily to albumin. Due to its quaternary ammonium structure, it has limited ability to cross lipid membranes and the blood-brain barrier, which reduces central nervous system exposure and associated side effects. The drug preferentially distributes to the lungs, exerting its bronchodilator effects locally.

Metabolism:
Tiotropium undergoes minimal hepatic metabolism. It is not extensively metabolized by the cytochrome P450 enzyme system and is therefore less susceptible to drug-drug interactions involving CYP enzymes. The limited metabolism primarily occurs via non-enzymatic ester cleavage. This metabolic profile contributes to its relatively predictable pharmacokinetics across patients with variable liver function.

Elimination:
Tiotropium is primarily excreted unchanged by the kidneys via renal tubular secretion and glomerular filtration. Approximately 74% of the inhaled dose is eliminated unchanged in the urine within 24 hours. The elimination half-life approximates 5 to 6 days, supporting once-daily dosing regimens. In patients with moderate to severe renal impairment, systemic exposure increases, necessitating cautious use and monitoring. Fecal excretion accounts for a minor elimination pathway.

Dosage Forms

Available Dosage Forms:
Tiotropium is available as an inhalation spray and as capsules for oral inhalation:
- Oral capsule (18 micrograms) for inhalation via HandiHaler device
- Oral inhalation spray formulation (Respimat inhaler), delivering doses of 1.25 micrograms per puff and 2.5 micrograms per puff

Dosages for Adults and Adolescents:
- For asthma maintenance in adults and children 6 years and older: 2 puffs once daily, each puff containing 1.25 mcg tiotropium, maximum 2 puffs (2.5 mcg) per 24 hours
- For treatment of bronchospasm caused by COPD in adults:
- Capsules: inhalation of powder from one 18 mcg Spiriva capsule via HandiHaler once daily (2 puffs total)
- Spray: 2 puffs once daily, each puff containing 2.5 mcg tiotropium
- Pediatric dosing for asthma in children younger than 6 years or COPD treatment in children: usage and dosage must be individually determined by the physician

Specific Patient Populations:
- Geriatric patients: no dosage adjustment needed based on studies showing similar pharmacokinetics and tolerability
- Patients with moderate to severe renal impairment: use with caution due to increased systemic exposure and risk of anticholinergic adverse effects; dose adjustment or avoidance may be necessary
- Patients with narrow-angle glaucoma, urinary retention, or bladder obstruction should use tiotropium with caution due to potential exacerbation of these conditions

Clinical guidelines recommend once-daily dosing based on the long half-life and sustained bronchodilatory effect of tiotropium with either delivery device.

Mechanism Of Action

Tiotropium is a long-acting anticholinergic agent belonging to the class of antimuscarinic bronchodilators. At the molecular level, it selectively and reversibly binds to the muscarinic M3 receptors located on airway smooth muscle cells. By competitively inhibiting acetylcholine binding to M3 receptors, tiotropium prevents receptor activation that otherwise leads to airway smooth muscle contraction and bronchoconstriction.

The blockade of M3 receptors results in long-lasting relaxation of bronchial smooth muscle, thereby maintaining airway patency and improving airflow. Tiotropium also exhibits a slower dissociation rate from M3 receptors compared to M2 receptors, contributing to its prolonged duration of action, typically around 24 hours, enabling once-daily dosing.

At the cellular signaling level, tiotropium inhibits acetylcholine-induced increase in intracellular calcium concentrations in airway smooth muscle cells. This reduces muscle contraction and airway hyperresponsiveness. Additionally, by reducing cholinergic tone, it decreases mucus secretion in the airways, further improving airway clearance and symptoms.

Clinically, tiotropium's mechanism contrasts with beta2-agonist bronchodilators, which act via adrenergic receptors to induce smooth muscle relaxation. Tiotropium offers complementary bronchodilation through cholinergic antagonism, often used in combination therapies for COPD and asthma maintenance. Its efficacy and safety profile is supported by multiple clinical trials demonstrating improved lung function, reduced exacerbations, and better quality of life in patients with obstructive pulmonary diseases.

Pharmacological Actions

Long-acting muscarinic receptor antagonist (LAMA) targeting primarily M3 receptors in bronchial smooth muscle
Causes sustained bronchodilation by preventing acetylcholine-induced bronchoconstriction
Reduces airway resistance and improves expiratory airflow in COPD and asthma
Decreases cholinergic-mediated mucus secretion in the respiratory tract
Exhibits a slow dissociation rate from muscarinic receptors prolonging duration of action
Minimal systemic anticholinergic effects due to poor systemic absorption and quaternary ammonium structure
Provides once-daily bronchodilation facilitating improved patient adherence
Adjuvant maintenance therapy for chronic respiratory diseases including COPD and asthma
Improves pulmonary function tests such as FEV1 and reduces exacerbation frequency
Synergistic effects when combined with beta2-agonists due to complementary mechanisms
Reduces dyspnea and improves exercise tolerance in patients with chronic lung diseases
Does not relieve acute bronchospasm; has no significant effect on inflammation
Minimal metabolism by cytochrome P450 enzymes, leading to low interaction potential
Exhibits anticholinergic side effects primarily localized to inhalation site in respiratory tract

Therapeutic Or Clinical Uses

Maintenance treatment of chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema
Prevention of bronchospasm in COPD patients
Adjunct therapy for asthma maintenance treatment in adults and children aged 6 years and older
Improvement of lung function and quality of life in obstructive airway diseases
Reduction in frequency and severity of COPD exacerbations
Management of airflow obstruction to improve breathing and symptoms
Used in combination with other bronchodilators and inhaled corticosteroids in asthma and COPD
Treatment for patients not adequately controlled on short-acting bronchodilators
Suitable for long-term once-daily treatment due to prolonged duration of action
Alternative to other long-acting bronchodilators in COPD and asthma management
Off-label use in selected cases of bronchospasm where antimuscarinic mechanism is beneficial
Supportive treatment to reduce hospital admissions and improve daily activity levels in COPD
Maintenance therapy aimed at reducing symptoms rather than treating acute episodes
Used in patients who may have intolerance or contraindications to beta2-agonists

Side Or Adverse Effects

Dry mouth, the most commonly reported side effect due to anticholinergic action
Pharyngeal irritation or sore throat following inhalation
Cough immediately following inhalation of the drug
Headache and dizziness, sometimes reported during early treatment
Blurred vision or visual disturbances due to accidental ocular exposure to powder
Paradoxical bronchospasm potentially life-threatening; immediate medical attention needed if breathing worsens
Constipation or gastrointestinal discomfort secondary to systemic anticholinergic effects
Urinary retention or difficulty in urination, particularly in patients with prostatic hypertrophy
Allergic reactions including rash, itching, angioedema, or anaphylaxis
Increased heart rate or palpitations reported rarely
Nausea and gastrointestinal upset
Chest pain or tightness, urgent evaluation advised if occurs
Swelling or puffiness of face, lips, tongue, or throat (angioedema)
Rare reports of fainting or irregular heartbeat
Mouth and throat dryness leading to increased risk of oral infections

Precautions

Use with caution in patients with narrow-angle glaucoma as tiotropium may increase intraocular pressure
Careful use indicated in patients with urinary retention or bladder outlet obstruction
Monitoring required in patients with moderate to severe renal impairment due to increased systemic exposure
Not intended to relieve acute bronchospasm; a rescue bronchodilator should be available
Avoid contact of inhalation powder with eyes to prevent ocular side effects
Instruct patients thoroughly on proper inhaler and capsule device use to avoid ineffective dosing or adverse effects
Use cautiously in elderly patients, although no specific dose adjustment is required
Potential for paradoxical bronchospasm; discontinue if worsening respiratory symptoms occur
Avoid adding other anticholinergic drugs unless prescribed and monitored carefully
Inform healthcare provider of all concurrent medications to assess for possible interactions
Pregnancy and breastfeeding use should be based on risk-benefit assessment due to limited data
Patients with hypersensitivity to any component of the formulation should avoid use
Assess patient for allergy to milk proteins as capsules contain lactose
Report any visual changes, pain, or discomfort in the eyes promptly during therapy
Not recommended for pediatric patients younger than 6 years due to lack of established safety

Warnings

May cause paradoxical bronchospasm that can be life-threatening; seek immediate medical attention for symptoms like increased wheezing or difficulty breathing
Potential to worsen narrow-angle glaucoma if powder contacts eyes; avoid eye exposure
Risk of urinary retention or difficulty urinating, especially in men with enlarged prostate
Precautions needed in patients with bladder outlet obstruction as tiotropium may exacerbate symptoms
Do not use as a rescue medication for acute bronchospasm because of delayed onset
Use of tiotropium capsules intended only with the HandiHaler device to prevent dosing errors
Capsules must not be swallowed; inhalation is the only approved route
Hypersensitivity reactions ranging from rash to anaphylaxis have been reported
Systemic anticholinergic effects may increase in patients with renal impairment
Risk of blurred vision and eye irritation; patients should be counseled to seek care for any ocular symptoms
Not to be used concurrently with other anticholinergic bronchodilators without physician supervision
Medication adherence critical to prevent respiratory deterioration; abrupt discontinuation may worsen symptoms
Caution advised when driving or operating machinery until individual response to medication is known, due to possible dizziness or blurred vision
In combination with other CNS depressants or antihistamines, additive side effects may occur
Patients should store inhalers properly and discard after recommended period (e.g., 3 months for Respimat)

Contraindication

Known hypersensitivity to tiotropium or any ingredient in the formulation
Allergy to atropine or atropine-like substances including ipratropium or oxitropium
Patients with milk protein allergy due to lactose excipient in tiotropium capsules
Acute bronchospasm or status asthmaticus requiring immediate relief therapy
Use of tiotropium capsules with any device other than the HandiHaler
Severe hypersensitivity reactions to anticholinergic agents
Patients with urinary retention of unknown etiology without close monitoring
Narrow-angle glaucoma uncontrolled or not adequately treated
Severe allergic reactions to bromide-containing medications
History of angioedema related to tiotropium therapy
Concurrent use with potassium citrate (not recommended due to significant interaction potential)
Patients with hypersensitivity to any anticholinergic medications belonging to muscarinic antagonists
Children under 6 years of age for asthma indication due to lack of established safety
Patients unable to properly use inhalation devices safely
Patients with severe renal failure who cannot be closely monitored

Drug Interactions

Concomitant use with potassium citrate is not recommended due to potential pharmacokinetic or pharmacodynamic interactions
Potential additive anticholinergic effects when combined with other anticholinergic drugs such as aclidinium, glycopyrrolate, ipratropium, oxybutynin, tolterodine, solifenacin, or scopolamine
Medications with anticholinergic properties including tricyclic antidepressants (amitriptyline, nortriptyline), antihistamines (diphenhydramine, chlorpheniramine), antipsychotics (clozapine, olanzapine), and muscle relaxants may potentiate side effects
Use with drugs like donepezil (cholinesterase inhibitors) may reduce therapeutic efficacy due to opposing mechanisms
Caution with CNS depressants and opioids like oxycodone and tapentadol due to increased risk of sedation and respiratory depression
Potential interaction with monoamine oxidase inhibitors and sympathomimetic agents
No significant interaction expected with CYP450-metabolized drugs as tiotropium is minimally metabolized by CYP enzymes
Concurrent use with inhaled corticosteroids or beta2-agonists is common and generally safe, providing complementary effects
Avoid concomitant use with other long-acting muscarinic antagonists without physician guidance to reduce risk of overdose
Medications that cause urinary retention or narrow-angle glaucoma may have additive adverse effects
Some interactions may require dose adjustments or monitoring if combined therapy is unavoidable
Interaction with herbal supplements possessing anticholinergic properties may enhance adverse effects
Smoking and alcohol may affect respiratory condition and medication efficacy, though direct pharmacokinetic interactions are minimal
Inform healthcare providers of all current medications to tailor therapy and prevent interactions
Monitoring for enhanced anticholinergic toxicity when combining multiple drugs with antimuscarinic effects

Preparations Of The Drug

Spiriva Capsules for Inhalation (18 micrograms tiotropium bromide) to be used exclusively with the HandiHaler device
Spiriva Respimat inhalation spray available as cartridges delivering 1.25 mcg or 2.5 mcg per puff
Each Respimat inhaler cartridge contains multiple doses (usually 30 or 60 puffs) with dose counter display
Dry powder formulations contained in sealed blister packs for capsules to ensure potency and protect from moisture
Respimat inhaler requires priming prior to first use and after periods of non-use for proper dose delivery
Capsules and inhalers supplied in temperature-controlled packaging to maintain drug stability
Inhalation powder formulations designed for targeted delivery to lower respiratory tract with minimal systemic absorption
HandiHaler device designed with piercing mechanism to puncture capsules and facilitate dose aerosolization
Powder formulations include lactose monohydrate as a carrier agent; not suitable for patients with lactose intolerance/allergy
Respimat inhaler uses aqueous solution propelled by mechanical energy to generate fine aerosol mist
Devices engineered for patient-friendly use with instructions to maximize drug delivery and minimize side effects
Packaging includes detailed patient information leaflet with instructions for inhaler assembly, use, cleaning, and storage
Different package sizes available including starter packs, refills, and multipacks depending on clinical need
Formulations are prescription-only requiring physician oversight for appropriate selection and monitoring
Manufactured under Good Manufacturing Practices to ensure consistent potency, purity, and safety